Mexico City, August 15, 2024 — The Ministry of Health has reported the detection of 49 cases of Mpox (previously known as monkeypox) in Mexico between January and August 3, 2024. These cases have been identified across eleven states, prompting heightened vigilance and action from health authorities to control the spread of the virus.
In addition to the confirmed cases, the National Committee for Epidemiological Surveillance (CONAVE) has indicated that there are 212 probable cases of Mpox under investigation. CONAVE, a coalition of health sector institutions, has issued an epidemiological notice to ensure medical units nationwide are vigilant in monitoring and reporting potential cases. This measure aims to curtail transmission chains and ensure that those affected receive timely medical care.
Enhanced Surveillance and Reporting Systems
Mexico’s epidemiological oversight is strengthened by the Mpox Epidemiological Surveillance System (SVE), which facilitates the reporting of probable cases through the National Epidemiological Surveillance System platform. This system allows for the efficient tracking and management of the virus, ensuring that cases are swiftly identified and managed.
All confirmed cases to date in Mexico involve clade II of the virus, with no detection of the new clade 1b variant, which has been a point of concern globally. The Ministry of Health continues to monitor for the emergence of any new variants.
National Response Plan Activated
In response to the ongoing Mpox cases, Mexico has activated its comprehensive Response Plan for Mpox. This plan includes a coordinated national response, community engagement, diagnostic and epidemiological surveillance, and clear risk communication strategies. The plan is continually updated to meet the evolving challenges posed by the Public Health Emergency of International Concern (PHEIC), under which this situation falls.
The Response Plan’s guidelines are publicly accessible and provide detailed instructions for health professionals and the general public on how to manage and prevent the spread of Mpox.
Clinical Stages and Symptomatology
Mpox typically presents in two clinical stages, both of which generally resolve within two to four weeks after the onset of symptoms. The initial stage, lasting approximately five days, is characterized by symptoms such as fever, severe headache, swollen lymph nodes, lower back pain, muscle aches, and extreme fatigue.
The second stage involves the appearance of small blisters, beginning one to three days after the fever’s onset. These blisters initially appear on the face before spreading to other parts of the body, marking the different phases of the rash.
Public Health Recommendations
Given the ongoing presence of Mpox in the country, the Ministry of Health has issued several recommendations to the general public to minimize the risk of infection:
- Wash hands frequently with soap and water or alcohol-based hand sanitizer.
- Cover the nose and mouth with the inside of the elbow when sneezing or coughing.
- Avoid sharing food, beverages, cutlery, and dishes.
- Wear a medical mask, especially in crowded or enclosed spaces.
- Clean and disinfect areas where an infected person has been present.
- Wash clothes, towels, and bed linens that have been in contact with an infected person using hot water and detergent.
- Avoid direct contact with the lesions of an infected person; if contact is necessary, use disposable gloves and dispose of them properly.
- Self-isolate if you exhibit symptoms to prevent further transmission.
Moving Forward
As Mexico continues to manage the ongoing public health challenge posed by Mpox, the Ministry of Health remains committed to ensuring the safety and well-being of its citizens. Through robust surveillance systems, effective response plans, and clear public health communications, Mexico aims to mitigate the impact of this virus and protect public health.
For more information on Mpox and the latest health advisories, the public is encouraged to consult official government websites and stay informed through credible news sources.